NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due to underlying cardiac conditions.

Trial Details

NCT ID
NCT06845319
Phase
PHASE2
Sponsor
Medical University of South Carolina
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Carboplatin
  • Paclitaxel
  • Pembrolizumab
Locations (sample)
  • Charleston, South Carolina, United States|32.77632,-79.93275

Key Eligibility Criteria

  • To be eligible to participate in this study, an individual must meet all of the following criteria:
  • Histologically confirmed triple-negative breast cancer (TNBC) or hormone receptor-low invasive breast carcinoma, with clinical anatomic Stage II or…
  • a) The invasive tumor must be hormone receptor-negative or low, defined as estrogen receptor (ER) and/or progesterone receptor (PR) staining presen…
  • b) HER2-negative disease, defined in accordance with current ASCO-CAP HER2 guidelines.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →